KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Pacira BioSciences (PCRX) over the last 3 years, with Q3 2025 value amounting to $626000.0.

  • Pacira BioSciences' Amortization of Deferred Charges fell 2547.62% to $626000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 663.52%. This contributed to the annual value of $3.1 million for FY2024, which is 447.26% up from last year.
  • As of Q3 2025, Pacira BioSciences' Amortization of Deferred Charges stood at $626000.0, which was down 2547.62% from $849000.0 recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Amortization of Deferred Charges ranged from a high of $937000.0 in Q1 2023 and a low of $626000.0 during Q3 2025
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $763000.0 (2024), whereas its average is $767818.2.
  • As far as peak fluctuations go, Pacira BioSciences' Amortization of Deferred Charges crashed by 2732.12% in 2024, and later soared by 2408.22% in 2025.
  • Pacira BioSciences' Amortization of Deferred Charges (Quarter) stood at $685000.0 in 2023, then rose by 23.5% to $846000.0 in 2024, then dropped by 26.0% to $626000.0 in 2025.
  • Its Amortization of Deferred Charges was $626000.0 in Q3 2025, compared to $849000.0 in Q2 2025 and $845000.0 in Q1 2025.